Answers are grounded in this paper and cite their sources.
Botulinum toxin (BoNT) has been approved for aesthetic use since 2002. Since then, clinical studies and expert use have informed our understanding of how BoNT exerts its clinical effect and the practical use of this product across a number of aesthetic applications. This review discusses the clinical properties and characteristics of abobotulinumtoxinA, which patients are suitable for its use, and how it can be utilized to treat facial rhytides.
No takes yet. Share an insight, caveat, or question.
Kane et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: